Nice hypothesis. Two issues.
Firstly, Wolgen has been as emphatic as humanly possible that with him in charge afamelanotide WILL NEVER be used for a cosmetic tan.
Secondly, Clinuvel over the last 5 years have reinterpreted the under promise over deliver mantra to under promise and then even with incredibly low expectations fail to meet them and set a new standard in under delivery.
How’s that vitiligo trial going? Wouldn’t mind an update.
Ann: Syd Capital Markets Briefing Presentation, page-73
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.52 |
Change
0.500(3.57%) |
Mkt cap ! $727.1M | |||
| Open | High | Low | Value | Volume |
| $14.26 | $14.65 | $14.03 | $3.232M | 223.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 385 | $14.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.57 | 520 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |